Objective: In this study, we investigated the muscle function of patients with haematological malignancy and healthy controls and examined the effect of cachexia on muscle function.
| INTRODUC TI ON
Patients with haematological malignancy present with various physical and mental symptoms, such as cytopenia derived from nutritional deficiencies and bone marrow suppression (Dehghani, Haddadi, & Vojdani, 2015; Kantarjian et al., 2007; Knight, Wade, & Balducci, 2004; Lyman, Poniewieraski, & Culakova, 2016) , nausea, vomiting, anorexia (Dehghani et al., 2015; Grunberg et al., 2010) , cancer-related fatigue (Hjermstand et al., 2005) and anxiety and depression (Bergerot et al., 2015; Hall et al., 2016) caused by the disease itself or the medications used. These symptoms can lead to a decrease in physical activity (Elter et al., 2009) , and it is assumed that physical function deterioration occurs as a result. Among the negative effects of cancer on physical function, muscle degradation is a particularly important issue. Vermaete Wolter Verhoef and Gosselink (2014) reported that patients with haematological malignancy have decreased muscle strength, including handgrip strength and quadriceps strength, starting in the pre-treatment period. Morishita et al. (2012) reported that among 164 patients with haematological malignancy in whom skeletal muscle mass (SMM) was measured using bioimpedance analysis (BIA), more than half were below the cut-off value for sarcopenia. Xiao et al. (2016) also reported that among 522 lymphoma patients who were able to undergo skeletal muscle area measurement at the third lumbar vertebral level by computed tomography, 47% were classified as having sarcopenia. In addition, Go et al. (2017) reported that sarcopenia was associated with intolerance to chemotherapy and poor prognoses in lymphoma patients. All these studies indicate the importance of focusing on skeletal muscle function when treating patients with haematological malignancy. However, these studies were all limited by the fact that muscle degradation related to the disease itself could not be distinguished from muscle weakness caused by ageing because adequately matched control groups were not included. Furthermore, it is possible that muscle degradation in patients with haematological malignancy is affected not only by a decrease in the amount of physical activity accompanying the above-mentioned physical and mental symptoms but also by factors such as cancer cachexia, which is the characteristic of cancer.
Cancer cachexia is defined as a multifactorial syndrome characterised by an ongoing loss of SMM (with or without loss of fat mass)
that cannot be fully reversed by conventional nutritional support, leading to progressive functional impairment .
Although the mechanism of cachexia is still unknown, the underlying pathology is characterised by a systemic inflammatory state mediated by inflammatory cytokines. This metabolic abnormality causes muscle wasting, loss of fat mass, increased resting energy expenditure, insulin resistance and decreased energy intake due to anorexia. The pathophysiology of this disease is evidently complex and multifactorial (Fearon, Glass, & Guttridge, 2012) . Some studies have investigated the relationship between cachexia and decreased muscle function in the context of solid tumours (Richards et al., 2012; Stephens et al., 2012; Tan & Fearon, 2008) . However, no previous reports have elucidated the relationship between cachexia and muscle function in patients with haematological malignancy.
Hence, this study aimed to clarify the features of muscle degradation related to the disease in patients with haematological malignancy using a carefully selected control group and to assess the effect of cachexia on muscle function. The novelty of this study was that we examined the features of muscle function in patients with haematologic malignancy and compared these with those of healthy controls to investigate the relationship between cachexia and muscle function in patients with haematologic malignancy and to examine body segments independently in order to quantify skeletal muscle mass according to muscle function.
| ME THODS

| Study design and participants
This cross-sectional observational study was conducted at Nagasaki University Hospital. The study was approved by the hospital ethics committee before the start of the study (approval number 15072757). Written informed consent was obtained from 
| Measurements
In patients with haematological malignancy, age, sex, body mass index (BMI), cancer type, disease duration and blood chemistry (Creactive protein [CRP] , albumin and haemoglobin) data within 3 days before the start date of the rehabilitation period were collected from medical records. In healthy controls, data on age, sex and BMI were collected. Both groups were evaluated for SMM, handgrip strength and isometric knee extensor strength on the start date of the rehabilitation period.
| Skeletal muscle mass
SMM was measured using BIA via a Physion MD (Physion Co., Ltd., Kyoto Japan). Impedance measurement was performed at a frequency of 50 kHz with a current of 500 μArms and impedance range of 10-1,500 Ω. Accuracy was ±1% ± 0.5 Ω (50-1,000 Ω) or ±2% ± 0.5 Ω (other impedance range), and the resolution capability was 0.1 Ω. All measurements were performed in the supine position with the arms slightly abducted from the body, forearms pronated and legs slightly apart. The impedance value of each body segment (upper arm, forearm, thigh, lower leg and trunk) was measured using two-lead BIA systems (distal first, proximal second). The current-introducing (source) electrodes were placed on the dorsal surface of the right and left metacarpal and metatarsal bones respectively. For the first distal lead measurement, voltage-sensing (detector) electrodes were placed on the middle point of the ulnar and radial styloid and the medial and lateral malleolus. For the second proximal lead measurement, the source electrodes were arranged in the same manner as those used for the first measurement while the detector electrodes were placed on the proximal ends of the radius and tibia. From these processes, the impedance value of each segment was measured, and SMM was calculated by programming. The validity of this equipment has been verified previously (Miyatani, Kanehisa, Masuo, Ito, & Fukunaga, 2001) and has been applied to the prediction of skeletal muscle volume (Ishiguro et al., 2006; Tanaka, Miyatani, Masuo, Fukunaga, & Kanehisa, 2007) .
The appendicular SMM was normalised for stature and referred to as the appendicular skeletal muscle mass index (SMI, kg/m 2 ).
| Handgrip strength
Handgrip strength was measured as a marker of general muscle strength using a standard adjustable-handle dynamometer (TKK 5101; Takei Scientific Instruments Co. Ltd., Niigata, Japan).
Measurements were taken in a standardised position with the participant standing with their arm held with zero abduction flush against the body. A single attempt at maximum right-and left-hand grip strength was recorded in kilogram force (kgf); the higher value was entered into the analysis.
If there was a difference in body size between the groups, the body weight ratio was also calculated to normalise these differences (% body weight ratio).
| Isometric knee extensor strength
Isometric knee extensor strength was measured as an index of lower-limb strength using hand-held dynamometers (HHDs; μ-tas F-1; ANIMA Co., Tokyo, Japan). Measurements were taken in the sitting position on a chair with the knee joint flexed at approximately 90°. The HHD sensor was placed on the distal anterior surface of the lower leg, and a belt was placed over the HHD and tied to the chair leg. Knee joint extension at maximum exertion was performed for approximately 5 s and repeated twice for each leg. The result was expressed in kgf, and the highest value was entered into the analysis.
If there was a difference in body size between the groups, the body weight ratio was also calculated to normalise this difference (% body weight ratio).
| Classification of patients with haematological malignancy by Glasgow Prognostic Score
The Glasgow Prognostic Score (GPS) was used to classify cachexia in patients with haematological malignancy. The GPS is an indicator of nutritional status and takes into account independent prognostic factors based on markers of inflammation such as CRP and albumin levels (Forrest, McMillan, McArdle, Angerson, & Dunlop, 2003) . Three groups were defined: patients with both elevated CRP (>10 mg/L) and hypoalbuminaemia (<3.5 g/L) were defined as having cachexia (cachexia); patients with either biochemical abnormalities were defined as having pre-cachexia (pre-cachexia); patients without these abnormalities were defined as not having cachexia (non-cachexia). The relationships between low food intake, systemic inflammatory response and GPS have been reported previously (Douglas & McMillan, 2014) . In addition, it was reported that the GPS objectively defines cachexia (McMillan, 2013) .
| Statistical analysis
The Mann-Whitney U test and chi-square test were used to compare patients with haematological malignancy and healthy controls. The
Kruskal-Wallis test was used to compare the three groups classified according to GPS. Values of p < 0.05 were considered statistically significant. Data were analysed using IBM SPSS Statistics version 23 software (IBM SPSS, Chicago, IL, USA).
| RE SULTS
Seventy-one patients with haematological malignancy and 71 healthy controls participated in the study. The demographic and diagnostic data are shown in Table 1 . There were no significant differences in age and sex between patients with haematological malignancy and healthy controls. Patients with haematological malignancy had lower BMI compared with healthy controls.
| Muscle function in patients with haematological malignancy and healthy controls
Patients with haematological malignancy had lower SMM of the total body and lower limbs, SMI, handgrip strength (kgf, % body weight ratio) and isometric knee extensor strength (kgf, % body weight ratio) than healthy controls. There was no significant difference in SMM of the upper limbs between the groups (Table 2) .
| Classification of patients with haematological malignancy by GPS
When classifying patients with haematological malignancy according to the GPS, 31 had no cachexia (43.7%), 23 had pre-cachexia (32.4%), and 17 had cachexia (23.9%). There was no significant difference in age, sex or BMI among the three groups. No significant difference was observed in SMM of the total body, upper and lower limbs and SMI. Finally, there was no significant difference among the three groups in handgrip strength and isometric knee extensor strength (Table 3) .
| D ISCUSS I ON
No previous studies to date have compared the muscle function of patients with haematological malignancy with that of healthy controls. Therefore, the effect of cachexia on muscle function in patients with haematological malignancy has not been clarified because the influence of ageing and sarcopenia were not excluded. In this study, we demonstrated that patients with haematological malignancy had decreased muscle function compared with healthy controls. However, when patients with haematological malignancy were divided into three groups (non-cachexia, pre-cachexia and cachexia),
there was no significant difference in muscle function. These results indicated that muscle function was reduced by disuse syndrome but not cachexia. This is the first study to clarify the characteristics of muscle function decline in patients with haematological malignancy.
The results of this study showed that patients with haematological malignancy had worse muscle function in terms of SMM of the total body and lower limb, SMI, handgrip strength and isometric knee extensor strength. Op den Kamp et al. (2013) showed that patients with progressive stages of non-small-lung cancer had lower appendicular SMM than did healthy controls. In addition, Navigante et al. (2013) reported that compared to healthy volunteers, solid tumour cancer patients exhibited significant decline in handgrip strength.
The present study obtained similar results in terms of SMM of the total body, SMI and handgrip strength. Furthermore, SMM of the lower limbs and isometric knee extensor strength were decreased in patients with haematological malignancy. In a previous study, Gray et al. (2011) showed that upper gastrointestinal cancer patients had reduced quadriceps volume compared with healthy controls when adjusted for age as a covariate. Moreover, Op den Kamp et al. (2013) reported that cancer patients had decreased lower-limb muscle strength.
In general, sarcopenia is classified as primary sarcopenia resulting from ageing or secondary sarcopenia caused by a reduction of physical activity, malnutrition and disease (Cruz-Jentoft et al., 2010) .
In this study, we excluded the influence of ageing by including an age-matched healthy control group. As a result, we inferred that Although the SMM of the upper limb was equal between the groups, handgrip strength differed between patients and healthy controls in this study. A previous study demonstrates that SMM should affect muscle strength (Reid, Naumova, Carabello, Phillips, & Fielding, 2008) . Therefore, our results suggest that factors other than SMM contribute to the muscle strength of patients with haematological malignancy. However, this hypothesis cannot be confirmed in this study and should be investigated in future studies. and a key feature of cancer cachexia. In particular, it was stated the highest hazard ratios were higher CRP and lower albumin level (Wallengren et al., 2013) . Therefore, we thought that GPS, which classifies cachexia based on CRP and albumin levels, is more suitable for this study. In cancer patients, the greatest incidence of TA B L E 3 Demographic data and muscle function of patients with haematological malignancy classified by Glasgow Prognostic Score weight loss, which is a characteristic of cachexia, is seen among patients with solid tumours, such as those of the gastric tract, pancreas, lung, colorectum and head and neck (Tan & Fearon, 2008) . Stephens et al. (2012) reported that cachectic gastrointestinal cancer patients had significantly reduced isometric knee extensor strength and cross-sectional area of the quadriceps muscle compared to non-cachectic cancer patients. Richards et al. (2012) identified a significant relationship between low SMI and elevated systemic inflammatory response as measured by the modified GPS in colorectal cancer patients. This finding was confirmed by the presence of a linear relationship between SMI and both CRP and albumin levels. In contrast, in the present study, only 17 of 70 (23.9%) patients had cachexia. This finding supports the results of the previous study by Tisdale (2009) . However, muscle function did not differ between the non-cachexia and pre-cachexia groups, which was an unexpected result. Matsuyama et al. (2015) reported that the incidence and severity of cachexia might vary among cancer types. Previous studies have reported that a high incidence of cachexia is present in patients with gastrointestinal, pancreatic and lung cancers, while fewer incidences occur in patients with breast cancer, non-Hodgkin's lymphoma and sarcomas (Bruera, 1997; Tisdale, 2009) . Moreover, the degree to which patients exhibit cachexia varies according to variations in tumour phenotype or even the host genotype, and these differences can contribute to the development of cancer cachexia. Therefore, it is believed that differences in the microenvironment in which tumour cells develop can affect the progression and phenotype of cancer cachexia (Matsuyama et al., 2015) . In patients with haematologic malignancy, the incidence of cachexia was low, and it was thought that the influence of cachexia on muscle function might be minimal because there was no significant difference in muscle function among the three groups classified by GPS. In this study, compared with healthy controls, patients with haematologic malignancy had lower SMM of the lower limbs which was a characteristic of disuse muscle atrophy. In addition, Courneya et al. (2009) reported that only 28.9% of lymphoma patients who received chemotherapy met the American College of Sports Medicine physical activity criteria. Moreover, Vallance, Courneya, Jones, and Reiman (2005) indicated that 33.8%, 6.5% and 23.7% of lymphoma patients met the physical activity criteria of public health exercise guidelines during the pre-diagnosis, treatment and post-treatment period respectively. Based on these facts, the muscle function of the three groups classified by GPS did not show any significant difference, because decreased physical activity, which induced muscle wasting, had greater effect on muscle dysfunction regardless of cachexia.
In this study, patients with haematological malignancy had lower muscle function, especially in the lower limbs. We excluded the influence of age-related sarcopenia by including an agematched healthy control group. Therefore, we can infer that the muscle degradation observed was influenced by reduced physical activity, malnutrition and cancer cachexia associated with disease and treatment rather than other factors. However, the influence of cachexia and malnutrition was minimal. In addition, the disease duration of patients with haematological malignancy is thought to be at least 1 year and perhaps longer, which is enough time for a reduction in physical activity to occur. This suggests that the reduction in muscle function might be affected by physical inactivity. However, it is very difficult to objectively evaluate the extent of patient's physical activity. Future studies will be required to clarify this issue.
In conclusion, in patients with haematological malignancy, muscle wasting and weakness were observed and were particularly pronounced in the lower limbs. However, the effect of cachexia was minimal, and the reduction in muscle function observed was mostly caused by muscle wasting, which accompanied a decline in physical activity.
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